Vietnam Anti-Rheumatic Drug Market is projected to register a strong CAGR during the forecast period (2026-2031).
Highlights:
- 1Regulatory AccelerationThe Vietnamese government is currently enlisting the Revised Pharmacy Law 2024 to shorten drug circulation registration from 12 months to 9 months for evaluation-referenced dossiers.
- 2Domestic Quality PivotTraphaco is currently accelerating its EU-GMP standard factory project to shift its revenue mix toward high-end modern medicine and international-standard anti-rheumatic products.
- 3Reimbursement ExpansionThe Ministry of Health is currently proposing 100% health insurance coverage for near-poor households and citizens aged 75 and older starting January 2026.
- 4Capacity GrowthDHG Pharma reported record net revenue in 2025, successfully enlisting its increased production scale to exceed pre-tax profit targets by 8.6%.
The Vietnamese anti-rheumatic drug market is currently experiencing a structural reset as a rapidly aging population, with 100% insurance coverage proposed for those over 75 starting in 2026, forces a surge in chronic disease management. Healthcare providers are responding to this demographic pressure by enlisting advanced DMARDs and biosimilars, which are successfully lowering the cost of long-term therapy for rheumatoid arthritis and lupus. This transition is becoming critical as the Revised Pharmacy Law 2024 is currently shortening registration timelines for changes not affecting quality from 3 months to 20 days, currently accelerating patient access to updated formulations. Regulatory influence is expanding through new e-commerce drug business methods, which are currently enabling pharmacy chains to rotate drugs and medicinal ingredients more efficiently across digital platforms. Consequently, the industry is reaching a structural outcome where local manufacturers like Traphaco and DHG Pharma are successfully enlisting EU-GMP upgrades to secure dominant positions in the hospital (EtC) procurement channel.
Market Dynamics
Drivers
Accelerated Digital Transformation: New 2025 regulations are successfully enlisting e-commerce drug business models, currently allowing pharmacy chains to operate with uniform quality management systems.
Aging Demographic Pressure: The rising prevalence of musculoskeletal disorders among the elderly is currently forcing the government to plan free annual health checks for all citizens starting in 2026.
Technology Transfer Incentives: The government is currently enlisting preferential policies for "technology transfer" drugs, encouraging multinational firms to localize the production of advanced anti-rheumatic molecules.
Public Health Modernization: Vietnam is currently enlisting sweeping reforms in preventive care, which is successfully increasing the early diagnosis of chronic inflammatory diseases.
Restraints and Opportunities
Strict E-commerce Controls: Wholesaling of controlled drugs via e-commerce remains prohibited, currently constraining the digital supply chain for certain potent pain management therapies.
Price Management Rigidity: New price announcement requirements for prescription drugs are currently forcing wholesalers to ensure that intermediate markups do not exceed publicly declared limits.
Biosimilar Localization (Opportunity): The revised law is currently enlisting incentives for domestically produced biopharmaceuticals, providing a clear path for local firms to launch biosimilar TNF-inhibitors.
Pharmacy Chain Expansion (Opportunity): The legalization of drug rotation within pharmacy chains is currently creating opportunities for high-volume distribution of OTC anti-rheumatic topical treatments.
Supply Chain Analysis
The Vietnamese pharmaceutical supply chain is currently transitioning from a "fragmented distribution" model to a "modernized pharmacy chain" structure to meet digital transformation goals. Distributors are successfully enlisting the newly granted right to rotate professional pharmaceutical personnel and drug stocks between chain nodes, currently reducing localized stockouts. This evolution is becoming critical as manufacturers like Imexpharm are reaching a structural outcome where record net profits are currently supporting the expansion of high-standard manufacturing lines to reduce reliance on imported specialty medicines.
Government Regulations
Regulation/Policy | Region | Impact on Market |
Revised Pharmacy Law 2024 | Vietnam | Takes effect July 1, 2025; currently shortens registration for changes from 3 months to 20 days. |
Resolution 72 (Public Health) | Vietnam | Proposed for Jan 2026; currently enlisting 100% insurance coverage for seniors over 75. |
Decision on E-commerce Drugs | Vietnam | Legalizes online retail for non-controlled drugs, currently enabling pharmacy chains to expand digital reach. |
Key Developments
DHG Pharma Board Restructuring (December 2025): The board appointed Mr. Toshifumi Kojima as Acting General Director (effective Jan 2026), currently enlisting his performance to guide the firm's 2026 orientation.
Traphaco CEO Transition (November 2025): Traphaco appointed Ms. Dao Thuy Ha as CEO for the 2021–2026 term, currently enlisting her leadership to target double-digit growth and EU-GMP factory completion by 2026.
Market Segmentation
By Type of Disease
Osteoarthritis and Rheumatoid Arthritis currently anchor the market, as the government is successfully enlisting free annual screenings to identify these conditions in early stages. Gout management is currently witnessing a transition toward modern pharmaceuticals as rising disposable incomes force a shift in lifestyle and diet-related disease patterns. This movement is resulting in an outcome where specialized Lupus treatments are reaching a structural reliance on biopharmaceuticals, currently supported by streamlined registration for innovative molecules.
By Type of Molecule
Traditional Pharmaceuticals currently dominate the market, but manufacturers are successfully enlisting technology-transfer contracts to produce high-quality generics locally. Biopharmaceuticals are currently witnessing the fastest demand shift as the Revised Pharmacy Law 2024 is currently providing a "strong impetus" for modern biological drug development. Consequently, the segment is reaching a structural outcome where local EU-GMP factories are becoming the mechanical necessity for competing in the high-value biological tender market.
By Sales Channel
The Prescription (EtC) channel currently accounts for the majority of total drugs circulated, as the government is successfully enlisting stricter wholesale price management to control hospital procurement costs. Over the Counter (OTC) sales are currently witnessing an expansion through e-commerce, as pharmacy chains are successfully enlisting "online" models to improve patient access to non-controlled analgesics. This shift is forcing an outcome where retail pharmacies must now adopt uniform quality systems to maintain their eligibility for chain operations.
List of Companies
Pfizer Inc.
AbbVie Inc.
F. Hoffmann-La Roche Ltd
DHG Pharma
Sun Pharmaceuticals Ltd.
Traphaco Joint Stock Company
Imexpharm Corporation
Domesco Medical Import-Export Joint Stock Corporation
Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company (Bidiphar)
Ha Tay Pharmaceutical Joint Stock Company (Hataphar)
Company Profiles
Traphaco Joint Stock Company: Strategically distinct for its "dual-engine" strategy, the company is successfully enlisting the leadership of Ms. Dao Thuy Ha to maintain its herbal medicine lead while accelerating EU-GMP modern medicine production.
DHG Pharma: Notable for its Japanese partnership (Taisho), the company is currently enlisting international governance standards to deliver 12.8% pre-tax profit growth, exceeding its 2025 fiscal targets.
Imexpharm Corporation: Distinguished by its high-quality focus, the company is successfully enlisting record net profits (up 9% in 2025) to support its fourth consecutive year of sustainable growth in the modern medicine sector.
Analyst View
The Vietnamese anti-rheumatic drug market is entering a "Regulatory-Led Expansion" phase. Success for participants now depends on successfully enlisting EU-GMP certification and technology-transfer partnerships to satisfy 2026 reimbursement expansions and navigate the shortened 9-month registration window for innovative treatments.
Vietnam Anti-Rheumatic Drug Market Scope:
| Report Metric | Details |
|---|---|
| Forecast Unit | USD Billion |
| Growth Rate | Ask for a sample |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Type of Disease, Type of Molecule, Type |
| Companies |
|
| Customization Scope | 15% Free Customization included with purchase — Request Custom Breakdown → |
| Sample & Data Access | PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample → |
Market Segmentation
By Type of Disease
- Osteoarthritis
- Rheumatoid Arthritis
- Gout
- Lupus
- Others
By Type of Molecule
- Pharmaceuticals
- Biopharmaceuticals
By Sales Channel
- Prescription
- Over-the-Counter (OTC)
Table of Contents
1. Introduction
1.1. Market Overview
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Function
4.4. Function Value Chain Analysis
5. Vietnam Antirheumatic Drug Market Analysis, By Type of Disease
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. Vietnam Antirheumatic Drug Market Analysis, By Type of Molecule
6.1. Introduction
6.2. Pharmaceuticals
6.3. Biopharmaceuticals
7. Vietnam Antirheumatic Drug Market Analysis, By Sales Channel
7.1. Introduction
7.2. Prescription
7.3. Over the Counter (OTC)
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Pfizer Inc.
9.2. AbbVie Inc.
9.3. F. Hoffmann-La Roche Ltd
9.4. DHG Pharma
9.5. Sun Pharmaceuticals Ltd.
9.6. Traphaco Joint Stock Company
9.7. Imexpharm Corporation
9.8. Domesco Medical Import-Export Joint Stock Corporation
9.9. Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company
9.10. Ha Tay Pharmaceutical Joint Stock Company
List of Figures
List of Tables
Frequently asked questions
What is the projected growth trajectory for the Vietnam Anti-Rheumatic Drug Market between 2026 and 2031?
The Vietnam Anti-Rheumatic Drug Market is projected to register a strong CAGR during the forecast period from 2026 to 2031. This growth is primarily driven by a rapidly aging population, with a proposed 100% health insurance coverage for those over 75 starting in 2026, which is increasing demand for chronic disease management. Additionally, regulatory acceleration through the Revised Pharmacy Law 2024 is shortening drug registration timelines, facilitating quicker patient access to new formulations.
What are the primary market dynamics driving demand in the Vietnam Anti-Rheumatic Drug Market from 2026 to 2031?
Key market dynamics include the significant aging demographic pressure, leading to a rising prevalence of musculoskeletal disorders, and government plans for free annual health checks starting in 2026. Accelerated digital transformation through new 2025 e-commerce drug business regulations also enables more efficient drug rotation. Furthermore, public health modernization and technology transfer incentives for advanced anti-rheumatic molecules are significantly contributing to market expansion.
Who are the leading domestic players in the Vietnam Anti-Rheumatic Drug Market and what strategies are they employing?
Local manufacturers such as Traphaco and DHG Pharma are securing dominant positions, particularly in the hospital (EtC) procurement channel. Traphaco is accelerating EU-GMP upgrades to shift its revenue mix towards high-end modern medicine and international-standard anti-rheumatic products. DHG Pharma reported record net revenue in 2025, leveraging its increased production scale to exceed pre-tax profit targets by 8.6%.
How is the regulatory environment impacting market access and reimbursement within the Vietnam Anti-Rheumatic Drug Market?
Regulatory influence is expanding significantly through reforms like the Revised Pharmacy Law 2024, which shortens drug circulation registration from 12 months to 9 months for evaluation-referenced dossiers and accelerates patient access. The Ministry of Health is also proposing 100% health insurance coverage for near-poor households and citizens aged 75 and older starting January 2026, substantially expanding reimbursement. However, strict e-commerce controls still prohibit the wholesaling of controlled drugs, presenting a specific restraint.
How are distribution channels, particularly e-commerce, transforming the Vietnam Anti-Rheumatic Drug Market?
New 2025 regulations are successfully enlisting e-commerce drug business models, allowing pharmacy chains to operate with uniform quality management systems and rotate drugs and medicinal ingredients more efficiently across digital platforms. This digital transformation is accelerating patient access and modernizing sales methods. However, the wholesaling of controlled drugs via e-commerce remains prohibited, which currently constrains certain aspects of digital distribution.
What are the emerging trends in anti-rheumatic drug therapies, specifically regarding advanced DMARDs and biosimilars in Vietnam?
Healthcare providers are increasingly enlisting advanced DMARDs and biosimilars to successfully lower the cost of long-term therapy for conditions like rheumatoid arthritis and lupus. This transition is critical in responding to demographic pressures and is supported by regulatory changes, such as shortened registration timelines, that accelerate patient access to updated formulations. The government also enlists preferential policies for 'technology transfer' drugs, encouraging the localization of advanced anti-rheumatic molecules.
Cite this report
Knowledge Sourcing Intelligence. (May 2026). Vietnam Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2026-2031). https://www.knowledge-sourcing.com/report/vietnam-anti-rheumatic-drug-market